Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58)

Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58) is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central